论文部分内容阅读
膀胱癌具有异质性特点 ,同期同级肿瘤的生物学行为可有很大的不同 ,用同一方法治疗的效果也会有差别 ,因此临床分期和病理分级已不能满足确定治疗方式及判断预后的需要。近年来发展起来的分子生物学对确定膀胱癌的恶性程度和预后有重要意义 ,有条件的医疗机构应对此进行不断探索 ,以期找到确定膀胱癌恶性程度更敏感而特异的分子生物学标志
Bladder cancer has the characteristics of heterogeneity, at the same level at the same level of biological behavior of the tumor can be very different, with the same method of treatment will be different, so the clinical stage and pathological grade can not meet the determination of treatment and prognosis need. In recent years, the development of molecular biology to determine the degree of malignancy and prognosis of bladder cancer is of great significance, conditional medical institutions should continue to explore this in order to find a more sensitive and specific to determine the degree of bladder cancer molecular biology markers